You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 6,312,939

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,312,939

Title:	Genetically engineered glutaminase and its use in antiviral and anticancer therapy
Abstract:	DNA encoding a therapeutically suitable glutaminase has been molecularly cloned. This allows one to obtain a polypeptide which is a therapeutically suitable glutaminase free of contaminating endotoxin. It has been found that this polypeptide is a potent anti-viral agent and when coupled to an anti-tumor monoclonal antibody is a potent anti-cancer agent. The glutaminase of the present invention is particularly useful for treating lung, breast and colon cancer cells and in the treatment of HIV-infected cells.
Inventor(s):	Roberts; Joseph (Columbia, SC), MacAllister; Thomas W (Columbia, SC), Sethuraman; Natarajan (Columbia, SC), Freeman; Abbie G. (Columbia, SC)
Assignee:	ME Medical Enzymes AG (St. Gallen, CH)
Application Number:	08/050,482
Patent Claims:	1. An E. coli cell which comprises a gene that encodes a therapeutically suitable glutaminase. 2. The cell of claim 1 which is deposited at the ATCC as accession no. 69117. 3. The cell of claim 1 which is capable of expressing said gene. 4. The cell of claim 1 wherein said gene has the nucleotide sequence shown in SEQ ID NO:1. 5. An isolated and purified DNA molecule comprising a nucleotide sequence coding for a therapeutically suitable glutaminase. 6. The DNA molecule of claim 5 wherein said glutaminase has a K.sub.m of 10.sup.-6 to 10.sup.-4 M for its reactants and remains active in human sera. 7. The DNA molecule of claim 5 wherein said glutaminase is a Pseudomonas glutaminase. 8. The DNA molecule of claim 5 wherein said glutaminase is a Pseudomonas 7A glutaminase. 9. The DNA molecule of claim 5 which comprises the nucleotide sequence shown in SEQ ID NO:1. 10. The DNA molecule of claim 6 wherein said molecule is capable of expressing said glutaminase in a recombinant cell. 11. The DNA molecule of claim 5 wherein said glutaminase has the sequence shown in SEQ ID NO:2. 12. The DNA molecule of claim 6 wherein expression of said glutaminase is controlled by an inducible promoter. 13. The DNA molecule of claim 6 wherein expression of said glutaminase is controlled by a repressor. 14. The DNA molecule of claim 6 wherein the promoter is tac. 15. The DNA molecule of claim 10 comprising a transcriptional terminator 3' and 5' to said sequence of glutaminase. 16. The DNA molecule of claim 8 having a methionine codon 5' to the initial lysine codon of mature glutaminase. 17. A cell according to claim 1, which comprises a Pseudomonas 7A glutaminase-asparaginase gene.

Details for Patent 6,312,939

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978	⤷ Try a Trial	2018-11-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.